Posts

Posted on

Palladyne AI Corp. Awarded Contract from Air Force Research Laboratory to Migrate Palladyne™ Pilot Autonomous Drone Software to Next-Generation AI Computing Chipsets

Palladyne AI Corp. Awarded Contract from Air Force Research Laboratory to Migrate Palladyne™ Pilot Autonomous Drone Software to Next-Generation AI Computing Chipsets

Palladyne Pilot AI software platform provides closed-loop autonomous detection, tracking, and control for unmanned aerial vehicles

SALT LAKE CITY–(BUSINESS WIRE)–Palladyne AI Corp. (NASDAQ: PDYN and PDYNW) (“Palladyne AI”), a developer of artificial intelligence software for robotic platforms in the commercial and defense sectors, today announced that the Company has been awarded a new contract from the Air Force Research Laboratory (AFRL) to migrate the Palladyne™ Pilot AI software platform (“Pilot”) to next-generation, U.S. made AI computing chipsets. This project will take place over a 26-month period beginning in early 2025.

The Palladyne Pilot software platform is based on the Closed Loop Ubiquitous Tasking and Control of Heterogeneous Exploring Sensors (CLUTCHES) framework, which defines a novel AI structure that combines upstream multi-sensor fusion with adaptive real-time sensor management on individual unmanned aerial vehicle (UAV) platforms to facilitate shared situational awareness. Pilot has been designed to enable a network of collaborating unmanned systems and multi-modal sensors that self-orchestrate to provide superior capabilities for applications including intelligence, surveillance, and reconnaissance (ISR). This real-time sensor management requires a closed-loop system, a key feature of the Pilot platform.

“Our development work with AFRL on the Pilot AI software platform has been critical to evolving the technology to benefit our DoD customers,” said Ben Wolff, CEO, Palladyne AI. “By evolving Pilot to be able to operate on these next-generation AI chipsets, in addition to the AI chipsets from Nvidia and Qualcomm that we are already operating on, we believe we will have the opportunity to deliver the benefits of our enhanced autonomy Pilot platform to the vast majority of small drone platforms that will be deployed in the coming years.”

“Palladyne AI has already made significant progress by porting its Pilot software platform to some of the latest AI chipsets currently available. Initial tests of the Pilot software are demonstrating strong potential to reduce the operational and cognitive burden on the warfighter while substantially improving mission effectiveness,” said Dr. Peter Zulch, AFRL. “We believe that Pilot will offer our Air Force drone operators a powerful tool for improving tactical missions, and by funding the migration of Pilot onto new and emerging AI chipsets we hope to expand the universe of small UAV platforms on which Pilot will be available.”

For more information on Palladyne AI and its artificial intelligence software for robotic platforms, please visit www.palladyneai.com. For more information about AFRL, please visit www.afrl.af.mil.

About Palladyne AI Corp.

Palladyne AI Corp. (NASDAQ: PDYN) has developed an advanced artificial intelligence (AI) and machine learning (ML) software platform poised to revolutionize the capabilities of robots, enabling them to observe, learn, reason, and act in a manner akin to human intelligence. Our AI/ML Software Platform empowers robots to perceive variations or changes in the real-world environment, enabling them to autonomously maneuver and manipulate objects accurately in response.

The Palladyne AI/ML Software Platform operates on the edge and dramatically reduces the significant effort required to program and deploy robots enabling industrial robots and collaborative robots (cobots) to quickly achieve autonomous capabilities even in dynamic and or complex environments. Designed to achieve precise results with minimal training time, limited data sets, and lower power requirements, compared to current solutions, Palladyne AI believes its software has wide application, including in industries such as automotive, aviation, construction, defense, general manufacturing, infrastructure inspection, logistics and warehousing. Its applicability extends beyond traditional robotics to include Unmanned Aerial Vehicles (UAVs), Unmanned Ground Vehicles (UGVs), and Remotely Operated Vehicles (ROVs). Palladyne AI’s approach is expected to elevate the return on investment associated with a diverse range of machines that are fixed, fly, float or roll.

By enabling autonomy, reducing programming complexity and enhancing efficiency, we are paving the way for a future where machines can excel in tasks that were once considered beyond their reach. For more information, please visit www.palladyneai.com and connect with us on LinkedIn at www.linkedin.com/company/palladyneaicorp.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the future uses of the Palladyne IQ software by the Air Force Research Laboratory, including during Phase II of the contract, the benefits of the software to the Air Force Research Laboratory, the capabilities or future capabilities of Palladyne AI’s software platform and products generally, the benefits of the software platform and products and the industries that could benefit from them, the impact of the software platform and products on robotics and the applicability of the software platform to different kinds of machines (such as UAVs, UGVs and ROVs and different available industrial robots). Forward-looking statements are inherently subject to risks, uncertainties, and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events, or results of operations, are forward-looking statements. These statements may be preceded by, followed by, or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or “continue” or similar expressions. Such forward-looking statements involve risks and uncertainties that may cause actual events, results, or performance to differ materially from those indicated by such statements. These forward-looking statements are based on Palladyne AI’s management’s current expectations and beliefs, as well as a number of assumptions concerning future events. However, there can be no assurance that the events, results, or trends identified in these forward-looking statements will occur or be achieved. Forward-looking statements speak only as of the date they are made, and Palladyne AI is not under any obligation and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Readers should carefully review the statements set forth in the reports which Palladyne AI has filed or will file from time to time with the Securities and Exchange Commission (the “SEC”), in particular the risks and uncertainties set forth in the sections of those reports entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements,” for a description of risks facing Palladyne AI and that could cause actual events, results or performance to differ from those indicated in the forward-looking statements contained herein. The documents filed by Palladyne AI with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov.

Investor Contact:

[email protected]

Press Contact:

[email protected]

KEYWORDS: Utah United States North America

INDUSTRY KEYWORDS: Automotive Drones Technology Other Defense Contracts Robotics Mobile/Wireless Defense Military Semiconductor Government Technology Autonomous Driving/Vehicles Nanotechnology Audio/Video Artificial Intelligence Telecommunications Software Networks Hardware Electronic Design Automation

MEDIA:

Logo
Logo
Posted on

Masco Corporation Announces Date for Earnings Release and Conference Call for 2024 Fourth Quarter and Full Year

Masco Corporation Announces Date for Earnings Release and Conference Call for 2024 Fourth Quarter and Full Year

LIVONIA, Mich.–(BUSINESS WIRE)–
Masco Corporation (NYSE: MAS) announced today that it will hold a conference call regarding 2024 fourth quarter and full year results on Tuesday, February 11, 2025, at 8:00 a.m. ET. The conference call will be hosted by Masco President and Chief Executive Officer Keith Allman. Participants in the call are asked to register five to ten minutes prior to the scheduled start time by dialing 800-549-8228 or 289-819-1520. Please use the conference identification number 48079.

The 2024 fourth quarter and full year results and supplemental material will be distributed at 7:00 a.m. ET on February 11 and will be available on the Company’s website at www.masco.com.

The conference call will be webcast simultaneously and in its entirety through the Masco Corporation website. Shareholders, media representatives and others interested in Masco may participate in the webcast by registering through the Investor Relations section on the Company’s website.

A replay of the call will be available on Masco’s website or by phone by dialing 888-660-6264 or 289-819-1325. Please use the playback passcode 48079 #. The telephone replay will be available approximately two hours after the end of the call and continue through March 11, 2025.

Headquartered in Livonia, Michigan, Masco Corporation is a global leader in the design, manufacture and distribution of branded home improvement and building products. Our portfolio of industry-leading brands includes Behr® paint; Delta® and hansgrohe® faucets, bath and shower fixtures; Liberty® branded decorative and functional hardware; and HotSpring® spas. We leverage our powerful brands across product categories, sales channels and geographies to create value for our customers and shareholders. For more information about Masco Corporation, visit www.masco.com.

Investor Contact

Robin Zondervan

Vice President, Investor Relations and FP&A

313.792.5500

[email protected]

KEYWORDS: Michigan United States North America

INDUSTRY KEYWORDS: Construction & Property Other Manufacturing Manufacturing Interior Design

MEDIA:

Logo
Logo
Posted on

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell engagers (TCE) in oncology. The expansion builds upon the successful partnership established in December 2022 and includes access to AbCellera’s TCE platform to develop therapeutic antibodies for tumor targets.

“We are pleased to broaden our AbbVie collaboration and look forward to using AbCellera’s TCE platform to bring novel cancer immunotherapies to patients in need,” said Carl Hansen, Ph.D., founder and CEO of AbCellera.

Under the terms of the agreement, AbCellera will lead discovery activities and AbbVie has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will receive upfront and research payments and is eligible to receive downstream milestone payments as well as tiered royalty payments on net sales.

About AbCellera’s T-Cell Engager Platform

CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on cancer-killing T cells at the same time. However, the development of T-cell engagers has been limited due to challenges with efficacy and safety. To address these challenges, AbCellera developed a T-cell engager platform that includes novel CD3-binding antibodies to expand the therapeutic window for this modality and costimulatory building blocks to enhance efficacy for difficult-to-treat cancers.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.

AbCellera Forward-Looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Inquiries


Media: Tiffany Chiu; [email protected], +1(236)521-6774

Partnering: Murray McCutcheon, Ph.D.; [email protected], +1(604)559-9005

Investor Relations: Peter Ahn; [email protected], +1(778)729-9116

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Pharmaceutical Health Oncology

MEDIA:

Logo
Logo
Posted on

Piper Sandler Expands Healthcare Investment Banking Team with the Addition of John Kerins

Piper Sandler Expands Healthcare Investment Banking Team with the Addition of John Kerins

NEW YORK–(BUSINESS WIRE)–Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of John Kerins as a managing director to the healthcare investment banking team. Kerins will continue to serve and support clients within the pharma services sector from the firm’s New York office.

“We are excited to welcome John to the team. His transaction experience combined with strong relationships across the pharma services landscape and with the leading healthcare private equity funds investing in the category are highly complementary to our healthcare investment banking practice. Pharma services is a rapidly growing segment of the market and a key focus for our healthcare investment banking platform. We are confident John’s skillset will enhance our ability to serve our clients and position Piper Sandler for long-term success in this market,” said J.P. Peltier, global group head of healthcare investment banking at Piper Sandler.

Prior to joining the firm, Kerins spent 10 years at Cain Brothers & Company, most recently as a managing director on their healthcare team advising clients on mergers and acquisitions. Before that, he was an investment banker at Deloitte for six years providing M&A advisory services. He received his bachelor’s degree from Kenyon College and his Master of Business Administration degree from Fordham University Gabelli School of Business.

“I am thrilled to be joining Piper Sandler. Their healthcare investment banking team has a trusted reputation of M&A leadership in addition to their deep healthcare services and biopharma research presence. I look forward to working with my new partners to further drive best-in-class client service,” said Kerins.

ABOUT PIPER SANDLER

Piper Sandler Companies (NYSE: PIPR) is a leading investment bank driven to help clients Realize the Power of Partnership®. Securities brokerage and investment banking services are offered in the U.S. through Piper Sandler & Co., member SIPC and NYSE; in the U.K. through Piper Sandler Ltd., authorized and regulated by the U.K. Financial Conduct Authority; in the EU through Aviditi Capital Advisors Europe GmbH, a tied agent of AHP Capital Management GmbH, authorized and regulated by BaFin; and in Hong Kong through Piper Sandler Hong Kong Ltd., authorized and regulated by the Securities and Futures Commission. Alternative asset management and fixed income advisory services are offered through separately registered advisory affiliates.

Follow Piper Sandler: LinkedIn | Facebook | X

©2025. Since 1895. Piper Sandler Companies. 800 Nicollet Mall, Minneapolis, Minnesota 55402-7036

Piper Sandler Companies

800 Nicollet Mall, Suite 900

Minneapolis, MN 55402

CONTACT

Nick Lawler

Tel: 212 891-8954

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

Logo
Logo
Posted on

LPL Financial Welcomes Advisor Marcus Alexander to Linsco Channel

SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that financial advisor Marcus S. Alexander, CPFA®, MBA, has joined LPL’s employee advisor channel, Linsco by LPL Financial, to launch Alexander Wealth Solutions. He reported serving approximately $340 million in advisory, brokerage and retirement plan assets* and joins LPL from Merrill Lynch. He will serve clients from LPL’s newest Linsco office in Newport Beach, Calif.

A native of Wimbledon, England, Alexander graduated from Loughborough University before moving to the States to earn his MBA from Duke University. As a well-educated businessman with great charisma and a knack for building relationships, Alexander was once told he should be a talk show host, but he chose to channel that energy into the world of investing.

“My passion is working with business owners, families and retirees to help guide them toward more secure financial futures,” said Alexander, a highly global and cultured thinker who has lived in Singapore, Boston and across the U.S. “I thoroughly enjoy investment planning and connecting with each client on a personal level to understand their specific goals, needs and dreams so that I can deliver results.”

Alexander’s search for greater autonomy and the ability to lean into his entrepreneurial spirit led him to Linsco by LPL Financial.

Why he made the move to LPL

“LPL’s dedication to independence, flexibility and mutually beneficial business relationships is what drew me to the firm,” Alexander said. “I’m excited to be part of an organization that equips me with the strategic resources and support necessary to develop a thriving advisory practice and deliver enhanced experiences to my clients.”

With Linsco, advisors have access to LPL’s integrated wealth management platform and robust business resources, along with the additional benefits of having support from an experienced branch management team and other dedicated consultants. This dynamic relationship gives advisors the ability to outsource things like real estate, technology, operations support and payroll so they can focus on what matters most: taking care of their clients.

“This move allows me to provide my clients with the resources of a large firm while also maintaining the independence and flexibility to run my business the way I want,” Alexander said. “Linsco is a perfect fit for me. I’m able to delegate to the strong team behind me while I’m out in the field meeting people and having important conversations with clients.”

Outside of work, Alexander has been an enthusiastic runner since his youth, having set several British age records in the 1500-meter and 3000-meter categories and competed in the IRONMAN 70.3 world championships, as well as the Boston Marathon. He’s an avid Duke Blue Devils college basketball fan and enjoys reading about science and astrophysics.

Scott Posner, LPL Executive Vice President, Business Development, said, “We welcome Marcus to the Linsco community, and we’re committed to being his long-term partner throughout the life cycle of his practice. At LPL, we provide financial advisors with the freedom to operate on their own terms, and innovative technology, comprehensive resources and strategic business solutions to help them deliver personalized advice and exceptional service experiences.”


Related

Advisors, learn how LPL Financial can help take your business to the next level.


About LPL Financial

LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports more than 28,000 financial advisors and the wealth management practices of 1,200 financial institutions, servicing and custodying approximately $1.8 trillion in brokerage and advisory assets on behalf of 6 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

Securities and advisory services offered through LPL Financial (LPL), a registered investment advisor and broker dealer, member FINRA/SIPC. LPL Financial and its affiliated companies provide financial services only from the United States.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

*Value approximated based on asset and holding details provided to LPL from end of year 2024


Media Contact:
 
[email protected] 
(704) 996-1840

Tracking #679050



Posted on

N2OFF, Inc. Announces 111 MWp Solar PV Project in Germany Secures Regulatory Approval

The approval was obtained from the Melz Municipal Committee in connection with the submission of Solterra’s statutory plan for the PV Project

Neve Yarak, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) — N2OFF, Inc.\ (NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for energy and innovation in the agri- tech sector, announced progress in its collaborative solar photovoltaic (PV) project in Melz, Germany, developed by Solterra Renewable Energy Ltd. (“Solterra”).

The project reached an important milestone with the Melz municipal committee approving the submission of the statutory plan for the facility, as announced on January 2, 2025. This approval follows an in-depth review of the project’s environmental and planning implications, and the Company believes represents an important step toward achieving ready-to-build (RTB) status, currently expected by the end of 2025. Following this approval the plan was submitted for a hearing process, which is one of the latest stages in the development process.

The Melz project, a 111 MWp solar PV facility, marks N2OFF’s first project in the renewable energy market, aligning the Company’s mission with its support for innovative and impactful sustainable energy projects.

The Melz project is part of a broader joint venture between N2OFF and Solterra aimed at accelerating the development of high-potential renewable energy facilities across Europe.

“We are proud to see the tangible progress being made in advancing this transformative project,” said David Palach, CEO of N2OFF. “This achievement reflects the strength of our collaboration with Solterra and our shared vision of delivering impactful solutions that promote clean energy and environmental sustainability.”

While N2OFF continues to provide financial support to Solterra, including a loan installment of €470,000 as part of a total €2 million loan commitment, the focus remains on accelerating project development to ensure its timely progression to RTB status.

About the Melz Project and Solterra Renewable Energy

The Melz project is one of Solterra’s flagship developments, representing its dedication to create renewable energy facilities with a total portfolio capacity of approximately 300 MW across Germany, Italy, and Poland. Founded in 2022 by renewable energy veterans Eran Litvak and Yair Harel, Solterra specializes in initiating and developing solar PV projects with rapid commercialization potential.

About N2OFF, Inc.:

N2OFF, Inc. (formerly known as Save Foods, Inc.) is a clean tech company engaged in sustainable solutions for energy and innovation in the agri-tech sector. Through its operational activities it delivers integrated solutions for sustainable energy, greenhouse gas emissions reduction and safety, quality solutions in the agri- tech market. NTWO OFF Ltd., N2OFF’s majority-owned Israeli subsidiary, aims to contribute in tackling greenhouse gas emissions, offering a pioneering solution to mitigate nitrous oxide (N2O) emissions, a potent greenhouse gas with 310 times the global warming impact of carbon dioxide. NTWO OFF Ltd., aims to promote agricultural practices that are both environmentally friendly and economically viable. N2OFF recently entered the solar PV market and will provide funding to Solterra. for the current project in the total Capacity of 111 MWp, as well as potential future projects. Save Foods Ltd., N2OFF’s majority-owned Israeli subsidiary, focuses on post-harvest treatments in fruit and vegetables to control and prevent pathogen contamination. N2OFF also has a minority ownership in Plantify Foods, Inc., a Canadian company listed on the TSXV that offers a wide range of clean-label healthy food options. For more information on Save Foods Ltd. and NTWO OFF Ltd. visit our website: www.n2off.com.

Forward-looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties including the success of our collaboration with Solterra, entry into future projects, our ability to successfully enter the solar PV sector, the profitability of such industry, and the potential added value of the increased capacity. Actual results, performance or achievements could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including market conditions as well as those discussed under the heading “Risk Factors” in N2OFF’s Annual Report on Form 10-K filed with the SEC on April 1, 2024, and in any subsequent filings with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.

Investor Relations Contacts:
Michal Efraty
[email protected]



Posted on

OneMedNet Regains Compliance with NASDAQ Listing Requirements

MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (“iRWD™”), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that the Company regained compliance with Nasdaq Listing Rule 5550(b)(2) (the “Rule”) after the market value of the Company’s common stock exceeded $35,000,000 for 10 consecutive business days. The Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming compliance with the Rule.   As a result, the Company has cleared all listing deficiency notices issued by Nasdaq.

Aaron Green, Chief Executive Officer, stated, “We are pleased to have now achieved compliance with the Nasdaq listing rules. This accomplishment will enable us to focus in 2025 on growing our revenue and business operations.”

During the 2024 and 2025, we developed and started to execute on our strategic plan by:

  • Expanding its product offerings, which now include data masking solutions for additional industries and subscription-based offerings for the Company’s healthcare and real-world data solutions.
  • Appointing Bob Golden as Chief Financial Officer to oversee enhancements in the Company’s financial reporting processes.
  • Hiring a Director of Business Development, Margaret Nash, and Vice President of Marketing, Michael Wong, to continue to build our commercial presence with Life Science organizations, additionally recently signing an agreement with Bayer’s AI Innovation Platform (AIIP) announced in early December 2024.
  • Enhancing our Data De-Identification and curation service leveraging Generative AI and deploying OneMedNet’s 2.0 generation indexer OMNi, to improve the speed and accuracy of data searching and indexing.
  • Refreshing the composition of the Company’s Board of Directors with three new directors who have relevant industry, financial and public company expertise.
  • Improving liquidity by raising approximately $6.4M in private placements with Off the Chain Capital and an affiliate of Discovery Capital Management.
  • Enhancing treasury management with a Bitcoin on the balance sheet strategy.

OneMedNet is now in a position to take advantage of the growing Real World Data market with a meaningful market share.

About OneMedNet Corporation

OneMedNet provides innovative solutions that unlock the significant value contained within the Real-World Data (“RWD”) repositories of over 1,400 healthcare system and provider sites that currently comprise its iRWD™ network. OneMedNet’s proprietary iRWD™ platform provides secure, comprehensive management of diverse clinical data types, including electronic health records, ECGs, EEGs, prescriptions, physician notes, laboratory results, and uniquely, medical imaging. Employing its robust iRWD™ platform, the Company securely de-identifies, searches, and curates the clinical data, bringing a wealth of internal and third-party research opportunities to its drug, medical device and imaging/diagnostic AI development customers.

OneMedNet’s platform is designed to address diverse clinical requirements across various domains, such as rare diseases, central nervous system disorders, oncology, cardiology and women’s health. The Company is committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of OneMedNet’s strategy to enhance patient outcomes and help pave the next wave of healthcare innovation. For more information, please visit www.onemednet.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

OneMedNet Contacts:

Michael Wong, VP Marketing
Email: [email protected]

SOURCE: ONEMEDNET CORPORATION



Posted on

UMB Announces Conference Call to Discuss Fourth Quarter and Full-Year 2024 Results

UMB Announces Conference Call to Discuss Fourth Quarter and Full-Year 2024 Results

KANSAS CITY, Mo.–(BUSINESS WIRE)–UMB Financial Corporation (Nasdaq: UMBF), a financial services company, will release earnings results for the fourth quarter 2024 after market hours on Tuesday, January 28, 2025. The company plans to host an investor conference call to discuss these results on Wednesday, January 29, at 8:30 a.m.(CT) / 9:30 a.m. (ET).

Interested parties may access the call by dialing (toll-free) 833-470-1428 or (international) 404-975-4839 and requesting to join the UMB Financial call with access code 099512. You may register in advance and receive a calendar invitation with call access details here: pre-registration.

The live webcast may also be accessed by visiting investorrelations.umb.com or by using the following the link:

UMB Financial 4Q 2024 Conference Call

A replay of the conference call may be heard through February 12, 2025, by calling (toll-free) 866-813-9403 or (international) 929-458-6194. The replay access code required for playback is 612758. The call replay may also be accessed at investorrelations.umb.com.

About UMB:

UMB Financial Corporation (Nasdaq: UMBF) is a financial services company headquartered in Kansas City, Missouri. UMB offers commercial banking, which includes comprehensive deposit, lending and investment services, personal banking, which includes wealth management and financial planning services, and institutional banking, which includes asset servicing, corporate trust solutions, investment banking, and healthcare services. UMB operates branches throughout Missouri, Illinois, Colorado, Kansas, Oklahoma, Nebraska, Arizona and Texas. The company also serves business clients nationwide and institutional clients in several countries. For more information, visit UMB.com, UMB Blog, UMB Facebook and UMB LinkedIn.

For more information please contact:

Stephanie Hague, 816.729.1027

[email protected]

KEYWORDS: United States North America Missouri

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

Posted on

INVESTOR REMINDER: Berger Montague Notifies Marqeta (NASDAQ: MQ) Investors of a Class Action Lawsuit and Deadline

PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) — Nationally recognized law firm Berger Montague PC informs investors that a lawsuit was filed against MARQETA, INC. (“Marqeta” or the “Company”) (NASDAQ: MQ) on behalf of purchasers of MARQETA securities between May 7, 2024 and November 4,2024, inclusive (the “Class Period”).

Investors that suffered losses from MARQETA (NASDAQ: MQ) investments can follow the link below for more information regarding the lawsuit:



CLICK HERE


to learn your rights.

Investors who purchased or acquired MARQETA securities during the Class Period may, no later than

FEBRUARY 7, 2025

, seek to be appointed as a lead plaintiff representative of the class.

Headquartered in Oakland, CA, Marqeta operates a cloud-based platform which enables businesses to issue and manage their own payment cards.

On November 4, 2024, the Company issued a press release entitled “Marqeta Reports Third Quarter 2024 Financial Results.” In addition to reporting its third quarter results, Marqeta announced lower fourth quarter guidance which reflected “several changes that became apparent over the last few months with regards to the heightened scrutiny of the banking environment and specific customer program changes.”

On this news, the price of Marqeta stock fell $2.53 per share – more than 42% – from a close of $5.95 per share on November 4, 2024 to close at $3.42 per share on November 5, 2024.


For additional information or to learn how to participate in this litigation,




CLICK HERE




or please contact Berger Montague: Andrew Abramowitz at




[email protected]




or (215) 875-3015, or Peter Hamner at




[email protected]


.

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.


Berger Montague
, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contacts:

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]  

Peter Hamner
Berger Montague PC
[email protected]



Posted on

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distributor in Israel with which the Company has entered into an agreement and plan of merger, received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group Co., Ltd. (“JAC Motors”), a globally recognized Chinese automotive company. This marks a significant milestone in AutoMax’s direct import and distribution operations, launched under agreements signed earlier this year with JAC Motors.

The shipment follows regulatory approvals for direct importation and positions AutoMax to begin marketing and sales activities for JAC Motors vehicles across Israel. 

JAC Motors has a strong focus on electric vehicles (“EVs”), making it a pioneer in sustainable transportation. The company has developed an impressive range of EVs, including passenger cars and commercial vehicles, supported by advanced R&D and cutting-edge battery technologies.  AutoMax sees JAC’s innovative EV lineup as an opportunity to meet the rising demand for electric vehicles in Israel, aligning with its strategy to bring sustainable transportation solutions to the local market.

SciSparc has provided financial support to AutoMax, which SciSparc believes helped provide AutoMax with resources to facilitate the transaction with JAC Motors.  Further, as part of its growth strategy, AutoMax entered into a merger agreement with the Company in April 2024, that if completed would pave the way for SciSparc’s expansion into the automotive sector.  The merger is subject to closing conditions, including the approval of the shareholders of each of the Company and AutoMax.

About SciSparc Ltd. (Nasdaq: SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.

Additional Information and Where You Can Find It

In connection with the proposed transaction between the Company and AutoMax, the Company has filed a preliminary registration statement, which includes a preliminary proxy statement/prospectus, with the Securities and Exchange Commission (the “SEC”). This press release is not a substitute for the registration statement, the proxy statement/prospectus or any other documents that the Company may file with the SEC or send to its shareholders in connection with the proposed transactions. Before making any voting decision, investors and securityholders are urged to read the final registration statement or the proxy statement/prospectus, as applicable, and all other relevant documents filed or furnished or that will be filed with or furnished to the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction and related matters.

You may obtain free copies of the proxy statement/prospectus and all other documents filed or that will be filed with the SEC regarding the proposed transaction at the website maintained by the SEC at www.sec.gov. Once filed, the final proxy statement/prospectus will be available free of charge on the Company’s website at https://investor.scisparc.com/, by contacting the Company’s Investor Relations at [email protected] or by phone at +972-3-6167055.

Participants in Solicitation

The Company, AutoMax and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of the Company’s Ordinary Shares in connection with the proposed transaction. Information about the Company’s directors and executive officers is set forth in the Company’s annual report on Form 20-F, for the year ended December 31, 2023, filed with the SEC on April 1, 2024. Other information regarding the interests of such individuals, as well as information regarding AutoMax’s directors and executive officers and other persons who may be deemed participants in the proposed transaction, will be set forth in the final proxy statement/prospectus, which will be filed with the SEC. You may obtain free copies of these documents as described in the preceding paragraph.

Non-Solicitation

This press release will not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses AutoMax’s growth strategy, that the merger potentially might pave the way for SciSparc’s expansion into the automotive sector, and AutoMax’s strategy to bring sustainable transportation solutions to the local market.  Since such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties related to the Company’s ability to complete the merger on the proposed terms and schedule, including risks and uncertainties related to the satisfaction of the closing conditions related to the Merger Agreement and risks and uncertainties related to the failure to timely, or at all, obtain shareholder approval for the transaction, and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the SEC on April 1, 2024, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
[email protected]
Tel: +972-3-6167055